- Home
- PLMR vs VERA Comparison
PLMR vs VERA Comparison
Compare PLMR & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLMR | VERA |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.0B |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PLMR | VERA |
|---|---|---|
| Price | $131.33 | $34.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $153.60 | $81.30 |
| AVG Volume (30 Days) | 206.3K | ★ 2.1M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.04 | N/A |
| EPS | ★ 3.51 | N/A |
| Revenue | ★ $875,967,000.00 | N/A |
| Revenue This Year | $192.25 | N/A |
| Revenue Next Year | $19.34 | $472.48 |
| P/E Ratio | $36.91 | ★ N/A |
| Revenue Growth | ★ 58.16 | N/A |
| 52 Week Low | $100.81 | $21.65 |
| 52 Week High | $147.62 | $56.05 |
Technical Indicators
Market Signals| Indicator | PLMR | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 50.81 | 50.07 |
| Support Level | $125.73 | $33.43 |
| Resistance Level | $136.48 | $42.77 |
| Average True Range (ATR) | 3.89 | 1.83 |
| MACD | 0.09 | 0.64 |
| Stochastic Oscillator | 71.15 | 60.19 |
Price Performance
Historical ComparisonAbout PLMR Palomar Holdings Inc.
Palomar Holdings Inc that provides property and casualty insurance products to individuals and businesses. It provides insurance products serving five categories: Earthquake, Inland Marine and Other Property, Casualty, Fronting, and Crop. Company distribute products through multiple channels, including retail agents, program administrators, wholesale brokers, and partnerships with other insurance companies. The company's Earthquake product generate high premium.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.